ARTICLE | Clinical News
Staccato loxapine regulatory update
December 21, 2009 8:00 AM UTC
Alexza submitted an NDA to FDA for Staccato loxapine to treat agitation in patients with schizophrenia or bipolar disorder. The compound is loxapine delivered by Staccato system inhaler. ...